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Plasma Triglycerides and
the Clinician: Time
for Reassessment*
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San Francisco, California
Not many years ago, abnormally high values of plasma choles-
terol were based on the upper fifth percentile of the population
distribution. This is now an anachronism given the extensive
body of evidence supporting the efficacy of cholesterol lower-
ing and the recommendations of the National Cholesterol
Education Program for primary and secondary prevention of
coronary heart disease. As for plasma triglycerides, normal
values are still based on the upper tail of the population
distribution, despite the increasing body of evidence that
increased triglyceride concentrations are at least as prevalent
among patients with premature atherosclerotic vascular dis-
ease and predict risk of first and recurrent coronary events.
In 1993, a National Institutes of Health Consensus Panel
(1) recommended consideration of triglyceride lowering in
certain high risk situations associated with fasting plasma
triglyceride concentrations .200 mg/dl, a value exceeding the
upper fifth percentile of the population distribution in adult
Americans (2,3). This recommendation was adopted in the
second report on adults of the National Cholesterol Education
Program (4). Other recent guidelines (5,6), perhaps influenced
by European studies indicating an association of plasma tri-
glycerides with coronary heart disease risk independent of high
density lipoprotein (HDL) cholesterol, have taken a slightly
more proactive stance, but likewise use a fasting triglyceride
concentration of 200 mg/dl as the discriminant for treatment.
Additional data published in the past few years have added
to the body of evidence that fasting plasma triglyceride con-
centrations are an independent risk factor for coronary heart
disease in men and women (7). Moreover, fasting plasma
triglycerides or measures related to increased concentrations
of triglyceride-rich lipoprotein remnants have been found (8,9)
to be independent predictors of increasing coronary artery
stenosis and associated clinical events in patients with coronary
heart disease. Finally, drug treatments that reduce the concen-
tration of plasma triglycerides and triglyceride-rich lipopro-
teins and increase HDL cholesterol concentrations have low-
ered the rate of progression of coronary artery lesions and
clinically related events (10–12). Although these outcomes
have generally been independent of levels of low density
lipoprotein (LDL) cholesterol, LDL particle size (another risk
factor) may have been favorably affected, and it has not been
possible in these studies to isolate the effect of changes in
individual lipoprotein classes.
The mechanisms by which triglyceride-rich lipoproteins (for
which fasting plasma triglycerides have been a useful surro-
gate) affect atherosclerotic lesions and clinical outcomes are
uncertain, but effects on hemostasis and thrombosis as well as
cholesterol accumulation in lesions may be involved (13).
Clearly, less is known about the pathophysiologic conse-
quences of hypertriglyceridemia than hypercholesterolemia.
In this issue of the Journal, Miller et al. (14) report on an
18-year follow-up of a study by the senior author, Thomas
Pearson (15), on risk factors for angiographically documented
coronary heart at The Johns Hopkins Hospital in the 1970s. A
single measurement of fasting plasma triglycerides and total
and HDL cholesterol was obtained on the morning of cathe-
terization. It should be noted that the values obtained by
Pearson (15) for these lipoprotein-bound lipids may have been
10% to 15% lower than those found in most studies because
the patients were supine rather than sitting when the blood
samples were taken. After certain exclusion criteria were
applied, 535 patients were entered into the current study, of
whom it was possible to contact 492. Of the 350 patients with
angiographically gradable coronary stenosis, 39% had died
from coronary heart disease-related events, and 18% had had
a nonfatal coronary event or had undergone coronary artery
revascularization. The investigators chose 100 mg/dl rather
than 200 mg/dl as the fasting plasma triglyceride cutpoint in
their analysis because it is close to the median value in
American and Canadian men and women (2). Mean fasting
triglyceride concentrations in the 199 cases were 160 mg/dl
compared with 137 mg/dl in those patients free of a coronary-
related event. Most notably, ;44% of patients with fasting
plasma triglycerides ,101 mg/dl remained free of an event
during the 18-year follow-up period compared with ;20% of
those with higher values. A multiple logistic regression analysis
showed that plasma triglycerides (relative risk 1.5), HDL
cholesterol (relative risk 1.5) and diabetes mellitus (relative
risk 2.1) were independent predictors of coronary events. Thus,
in this study, unexceptional fasting triglyceride concentrations
(as low as 101 to 134 mg/dl in a quartile analysis) may have
been deleterious to patients with established coronary heart
disease. Given the variability of fasting plasma triglyceride
concentrations and the close inverse relation of triglycerides
and HDL cholesterol, the triglyceride-associated risk could
well be greater.
Whether similar findings would apply to a coronary heart
disease-free population is unclear. However, as pointed out by
the authors of the current study, some large prospective
population studies in this country and abroad also suggest that
levels considerably ,200 mg/dl may be deleterious.
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Currently, many patients who survive a myocardial infarc-
tion are treated with lipid-lowering drugs that reduce plasma
triglycerides as well as LDL cholesterol. Nicotinic acid, drugs
of the fibrate class and atorvastatin can reduce triglyceride
concentrations by 40% to 50%. Moreover, all these classes of
drugs reduce the cholesterol content of triglyceride-rich li-
poproteins disproportionately (16). Thus, many patients with
coronary heart disease whose plasma triglyceride levels are
well below 200 mg/dl are already being treated with plasma
triglyceride and triglyceride-rich lipoprotein-lowering medica-
tions. The report of Miller et al. (14) focuses attention on the
need for investigations of the basis for the common elevations
of triglyceride-rich lipoproteins in patients with atherosclerotic
cardiovascular disease and the potential specific benefit of
triglyceride lowering. At the same time, their observations lend
support to the use of non-HDL cholesterol (total plasma
cholesterol minus HDL cholesterol) for atherosclerotic risk
screening (17,18). This simple measurement, which includes
triglyceride-rich lipoprotein cholesterol, as well as cholesterol
in other atherogenic lipoproteins, can be obtained in nonfast-
ing subjects, reserving triglyceride measurements for otherwise
high risk situations. Non-HDL cholesterol may be a better
guide than LDL cholesterol to the overall efficacy of lipid-
lowering treatments once the lipoprotein abnormality has been
established.
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Abbreviations and Acronyms
HDL 5 high density lipoprotein
LDL 5 low density lipoprotein
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